Ramat Gan-based Predix Pharmaceuticals Holdings, Inc. has agreed to be acquired by US-based EPIX Pharmaceuticals Inc. for $90 million, including the assumption of net debt at closing.
EPIX will pay shareholders of privately held Predix approximately $35 million in cash, stock, or a combination of both, depending on the achievement of certain clinical and strategic milestones, as well as 47% of the combined company's shares outstanding.
Predix President and CEO Dr. Michael G. Kauffman will become the CEO of the combined company.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>